Table 2.
Characteristics of mTNBC patients by NLR and PLR.
| Total (n = 57) | NLR <2.5 (n = 25) | NLR ≥2.5 (n = 32) | p value | PLR <200 (n = 34) | PLR ≥200 (n = 23) | p value | |
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | |||
| Pts age | |||||||
| <50 yrs | 21 (36.8%) | 3 (5.2%) | 18 (31.6%) | <0.001 | 9 (15.8%) | 12 (21%) | 0.048 |
| >50 yrs | 36 (63.2%) | 22 (38.6%) | 14 (24.6%) | 25 (43.9%) | 11 (19.3%) | ||
| Previous taxane | |||||||
| Yes | 43 (75.4%) | 16 (28%) | 27 (47.4%) | 0.076 | 25 (43.8%) | 18 (31.6%) | 0.68 |
| No | 14 (24.6%) | 9 (15.8%) | 5 (8.8%) | 9 (15.8%) | 5 (8.8%) | ||
| Visceral disease | |||||||
| Yes | 37 (64.9%) | 16 (28%) | 21 (36.8%) | 0.9 | 23 (40.3%) | 14 (24.6%) | 0.6 |
| No | 20 (35.1%) | 9 (15.8%) | 11 (19.4%) | 11 (19.3%) | 9 (15.8%) | ||
| N. metastatic sites | |||||||
| 1–2 | 36 (63.2%) | 18 (31.6%) | 18 (31.6%) | 0.22 | 23 (40.3%) | 13 (22.8%) | 0.39 |
| >2 | 21 (36.8%) | 7 (12.3%) | 14 (24.5%) | 11 (19.3%) | 10 (17.6%) | ||
| ChT type | |||||||
| Taxane | 48 (84.2%) | 20 (35.1%) | 28 (49.1%) | 0.48* | 28 (49.1%) | 20 (35.1%) | 0.7* |
| Gemcitabine | 9 (15.8%) | 5 (8.8%) | 4 (7%) | 6 (10.5%) | 3 (5.3%) | ||
| Maintenance ChT | |||||||
| Yes | 14 (24.6%) | 10 (17.6%) | 4 (7%) | 0.017 | 11 (19.3%) | 3 (5.3%) | 0.097 |
| No | 43 (75.4%) | 15 (26.3%) | 28 (49.1%) | 23 (40.3%) | 20 (35.1%) | ||
Pts = patients; ChT = chemotherapy.
*Fisher’s exact test.